| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3335 | 2013 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 458 | 2020 |
| External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative … TJ Whelan, JA Julian, TS Berrang, DH Kim, I Germain, AM Nichol, M Akra, ... The Lancet 394 (10215), 2165-2172, 2019 | 401 | 2019 |
| Adjuvant therapy for completely resected stage II colon cancer A Figueredo, ME Coombes, S Mukherjee Cochrane Database of Systematic Reviews, 2008 | 387 | 2008 |
| Breast cancer chemotherapy induces the release of cell‐free DNA, a novel procoagulant stimulus LL Swystun, S Mukherjee, PC Liaw Journal of Thrombosis and Haemostasis 9 (11), 2313-2321, 2011 | 215 | 2011 |
| Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial PJ Goodwin, RJ Segal, M Vallis, JA Ligibel, GR Pond, A Robidoux, ... Journal of clinical oncology 32 (21), 2231-2239, 2014 | 197 | 2014 |
| Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study YJ Ko, CM Canil, SD Mukherjee, E Winquist, C Elser, A Eisen, ... The lancet oncology 14 (8), 769-776, 2013 | 166 | 2013 |
| Effect of metformin vs placebo on invasive disease–free survival in patients with breast cancer: the MA. 32 randomized clinical trial PJ Goodwin, BE Chen, KA Gelmon, TJ Whelan, M Ennis, J Lemieux, ... Jama 327 (20), 1963-1973, 2022 | 164 | 2022 |
| Effect of metformin vs placebo on weight and metabolic factors in NCIC CTG MA. 32 PJ Goodwin, WR Parulekar, KA Gelmon, LE Shepherd, JA Ligibel, ... Journal of the National Cancer Institute 107 (3), djv006, 2015 | 151 | 2015 |
| Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate … F Saad, S Hotte, S North, B Eigl, K Chi, P Czaykowski, L Wood, M Pollak, ... Clinical Cancer Research 17 (17), 5765-5773, 2011 | 144 | 2011 |
| Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area H Mir, M Alhussein, S Alrashidi, H Alzayer, A Alshatti, N Valettas, ... Canadian Journal of Cardiology 34 (8), 1059-1068, 2018 | 142 | 2018 |
| A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer … KN Chi, EY Yu, C Jacobs, J Bazov, C Kollmannsberger, CS Higano, ... Annals of Oncology 27 (6), 1116-1122, 2016 | 109 | 2016 |
| Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study DP Leong, V Fradet, B Shayegan, E Duceppe, R Siemens, T Niazi, L Klotz, ... The Journal of urology 203 (6), 1109-1116, 2020 | 107 | 2020 |
| A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium SS Sridhar, E Winquist, A Eisen, SJ Hotte, E McWhirter, IF Tannock, ... Investigational new drugs 29, 1045-1049, 2011 | 103 | 2011 |
| Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label … KN Chi, CS Higano, B Blumenstein, JM Ferrero, J Reeves, S Feyerabend, ... The lancet oncology 18 (4), 473-485, 2017 | 94 | 2017 |
| Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial DP Leong, T Cosman, MM Alhussein, N Kumar Tyagi, S Karampatos, ... Cardio Oncology 1 (1), 1-10, 2019 | 89 | 2019 |
| Is red meat intake a risk factor for breast cancer among premenopausal women? VH Taylor, M Misra, SD Mukherjee Breast cancer research and treatment 117 (1), 1-8, 2009 | 87 | 2009 |
| Tn-MUC1 DC vaccination of rhesus macaques and a phase I/II trial in patients with nonmetastatic castrate-resistant prostate cancer E Scheid, P Major, A Bergeron, OJ Finn, RD Salter, R Eady, ... Cancer immunology research 4 (10), 881-892, 2016 | 73 | 2016 |
| Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials MAM Farooqi, N Malhotra, SD Mukherjee, S Sanger, SK Dhesy-Thind, ... PloS one 13 (12), e0209486, 2018 | 70 | 2018 |
| Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with … G Attard, JS De Bono, CJ Logothetis, K Fizazi, SD Mukherjee, AM Joshua, ... Clinical cancer research 21 (7), 1621-1627, 2015 | 61 | 2015 |
Kim N. ChiProfessor of Medicine, University of British ColumbiaZweryfikowany adres z bccancer.bc.ca
